RHYTHM PHARMACEUTICALS, INC.

RYTM

$7.40B

Mid Cap

NASDAQBiotechnology🇺🇸North America283 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 30, 2026

20w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 1 past

🎯PDUFANext

✅Approved

FDA PDUFA Date IMCIVREE (priority)

3/14/2026

For obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date setmelanotide (priority)

6/30/2026

For Bardet-Biedl syndrome and other rare genetic diseases of obesity. NDA filing. Extracted from SEC filing: 8-K

Source

⭐Phase 3

Setmelanotide Phase 3 Results Expected

Sep 30, 2026Setmelanotide39

Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity

Source

Phase 2

Setmelanotide Phase 2 Results Expected

Oct 31, 2026Setmelanotide20

Primary completion for Setmelanotide trial (NCT06772597) in Prader-Willi Syndrome

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Class I or III Antiarrhythmic Medications

Phase 3

Atrial Fibrillation

Setmelanotide

Phase 3

Genetic Obesity

Flecainide or Sotalol or Propafenone

Phase 3

Paroxysmal Atrial Fibrillation

Setmelanotide 2 mg

Phase 3

Bardet-Biedl Syndrome

Part C: RM-718

Phase 2

Hypothalamic Obesity

LB54640

Phase 2

Hypothalamic Obesity

Diuretics

Phase 2

Heart Failure

Drug Name	Phase	Indication	Designations
Class I or III Antiarrhythmic Medications	Phase 3	Atrial Fibrillation	-
Setmelanotide	Phase 3	Genetic Obesity	-
Flecainide or Sotalol or Propafenone	Phase 3	Paroxysmal Atrial Fibrillation	-
Setmelanotide 2 mg	Phase 3	Bardet-Biedl Syndrome	-
Part C: RM-718	Phase 2	Hypothalamic Obesity	-
LB54640	Phase 2	Hypothalamic Obesity	-
Diuretics	Phase 2	Heart Failure	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

RYTM News